AccScience Publishing / AN / Online First / DOI: 10.36922/AN025460115
Submit to AN
Cite this article
1
Download
24
Views
Journal Browser
Volume | Year
Issue
Search
Forthcoming Issue
Current Issue
View All
News and Announcements
View All
REVIEW ARTICLE

Pathophysiological signaling and therapeutic potential of protein kinases in Alzheimer’s disease: A comprehensive review

Jahngeer Alam1* ,  Anushka Kalash2 ,  Shafaque Reyaz3
Show Less
1 Department of Pharmacology, Faculty of Medicine, Aligarh Muslim University, Aligarh, Uttar Pradesh, India
2 Department of Pharmacology, School of Pharmaceutical Sciences, Jaipur National University, Jaipur, Rajasthan, India
3 Department of Pharmacology, Delhi Institute of Pharmaceutical Sciences and Research, New Delhi, India
Advanced Neurology, 025460115 https://doi.org/10.36922/AN025460115
Received: 10 November 2025 | Revised: 17 February 2026 | Accepted: 20 March 2026 | Published online: 8 May 2026
© 2026 by the Author(s). This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution 4.0 International License ( https://creativecommons.org/licenses/by/4.0/ )
Download PDF
XML
Cite
Abstract

Alzheimer’s disease (AD), a progressive neurodegenerative disorder, is characterized by the formation of plaques of amyloid proteins and tangles of tau proteins, which disrupt neuronal communication and eventually lead to neuronal death. The pathological mechanisms underlying AD are complex, with tau protein hyperphosphorylation playing a central role in disease progression. Several kinases, including microtubule affinity-regulating kinase (MARK), cyclin-dependent kinase-5 (CDK-5), and glycogen synthase kinase-3 (GSK-3), have been identified as key regulators of tau phosphorylation. Abnormal activity of these enzymes has been associated with hyperphosphorylation of tau proteins, leading to synaptic dysfunction, neuronal death, and impaired memory. Moreover, other protein kinases, such as protein kinase C and Rho kinase, contribute to neurodegeneration by disrupting intracellular signaling essential for neuronal survival. Given these critical roles of such enzymes in AD pathogenesis, several therapeutic strategies targeting tau-associated pathways have gained significant attention in recent years. Multiple clinical trials are also underway to develop effective anti-tau treatments, including drugs targeting tyrosine kinases, GSK-3, and mitogen-activated protein kinase (MAPK). Over the past decades, there has been a growing research emphasis on the role of protein kinases in AD and on identifying and validating potential enzymatic targets for AD management. This review provides an in-depth analysis of the molecular mechanisms by which various protein kinases induce tau-associated neurodegeneration and emphasizes emerging therapeutic strategies targeting kinase-mediated signaling pathways, offering new perspectives for AD management.

Keywords
Protein kinases
Alzheimer’s disease
Tau protein
Hyperphosphorylation
Serine/Threonine kinases
Protein tyrosine kinases
Funding
None.
Conflict of interest
The authors declare no conflict of interest.
References
  1. Alam J. Vitamins: a nutritional intervention to modulate the Alzheimer’s disease progression. Nutr Neurosci. 2022;25:945- 962. doi: 10.1080/1028415X.2020.1826762.

 

  1. Cummings JL, Gonzalez MI, Pritchard MC, et al. The therapeutic landscape of tauopathies: challenges and prospects. Alzheimers Res Ther. 2023;15:168. doi: 10.1186/s13195-023-01321-7.

 

  1. Alam J, Bhattacharjee S, Chakraborty S, et al. Chapter 25 - Neuromodulation via brain stimulation: A promising therapeutic perspective for Alzheimer’s disease. In： Artificial Intelligence in Biomedical and Modern Healthcare. 2025,257-266. doi: 10.1016/B978-0-443-21870-5.00025-x

 

  1. SharmaL, Sharma A, Goyal R, et al. Pinus Roxburghii Sarg. ameliorates Alzheimer’s disease-type neurodegeneration and cognitive deficits caused by intracerebroventricular-streptozotocin in rats: An in vitro and in vivo study. Indian J Pharm Sci. 2020;82(5):861-870. doi: 10.36468/pharmaceutical-sciences.715

 

  1. Alam J, Jaiswal V, Sharma L. Screening of Antibiotics Against β-amyloid as Anti-amyloidogenic Agents: A Drug Repurposing Approach. Curr Comput Aided Drug Des. 2021;17(5):647-654. doi: 10.2174/1573409916666200703171732

 

  1. Alam J, Kalash A, Kulshrestha A. Molecular Signalling Pathways in Alzheimer’s Disease and Their Therapeutic Implications. J Neuro Res. 2025;15(1):1-11. doi: 10.14740/jnr869

 

  1. Ju Y, Tam KY. Pathological mechanisms and therapeutic strategies for Alzheimer’s disease. Neural Regen Res. 2022;17(3):543-549. doi: 10.4103/1673-5374.320970

 

  1. Buchholz S, Zempel H. The six brain-specific TAU isoforms and their role in Alzheimer’s disease and related neurodegenerative dementia syndromes. Alzheimers Dement. 2024;20(5):3606-3628. doi: 10.1002/alz.13784

 

  1. Li Z, Yin B, Zhang S, et al. Targeting protein kinases for the treatment of Alzheimer’s disease: Recent progress and future perspectives. Eur J Med Chem. 2023;261:115817. doi: 10.1016/j.ejmech.2023.115817

 

  1. Priya K, Siddesha JM, Dharini S, et al. Interacting Models of Amyloid-β and Tau protein: An Approach to Identify Drug Targets in Alzheimer’s Disease. J Alzheimers Dis Rep. 2021;5(1):405-411. doi: 10.3233/ADR-210018

 

  1. Dhapola R, Beura SK, Sharma P, et al. Oxidative stress in Alzheimer’s disease: current knowledge of signalling pathways and therapeutics. Mol Biol Rep. 2024;51(1):48. doi: 10.1007/s11033-023-09021-z

 

  1. Alam J, Sharma L. Potential Enzymatic Targets in Alzheimer’s: A Comprehensive Review. Curr Drug Targets. 2019;20(3):316-339. doi: 10.2174/1389450119666180820104723

 

  1. Alam J, Kalash A, Hassan MI, et al. Agents at the Peak of US FDA Approval for the Treatment of Alzheimer’s Disease. Neurol Res. 2024;46(4):318-325. doi: 10.1080/01616412.2024.2302271

 

  1. Cummings J, Zhou Y, Lee G, et al. Alzheimer’s disease drug development pipeline: 2024. Alzheimers Dement. 2024;10(2):e12465. doi: 10.1002/trc2.12465

 

  1. Viorel VI, Pastorello Y, Bajwa N, et al. p38-MAPK and CDK5, signalling pathways in neuroinflammation: a potential therapeutic intervention in Alzheimer’s disease? Neural Regen Res. 2024;19(8):1649-1650. doi: 10.4103/1673-5374.389645

 

  1. Ye J, Wan H, Chen S, et al. Targeting tau in Alzheimer’s disease: from mechanisms to clinical therapy. Neural Regen Res. 2024;19(7):1489-1498. doi: 10.4103/1673-5374.385847

 

  1. Gholami A. Alzheimer’s disease: The role of proteins in formation, mechanisms, and new therapeutic approaches. Neurosci Lett. 2023;817:137532. doi: 10.1016/j.neulet.2023.137532

 

  1. Turab Naqvi AA, Hasan GM, Hassan MI. Targeting Tau Hyperphosphorylation via Kinase Inhibition: Strategy to Address Alzheimer’s Disease. Curr Top Med Chem. 2020(12);20:1059-1073. doi: 10.2174/1568026620666200106125910

 

  1. Lauretti E, Dincer O, Praticò D. Glycogen synthase kinase-3 signalling in Alzheimer’s disease. Biochim Biophys Acta Mol Cell Res. 2020;1867(5):118664. doi: 10.1016/j.bbamcr.2020.118664

 

  1. Woodgett JR. Molecular cloning and expression of glycogen synthase kinase-3/factor A. EMBO J. 1990;9(8):2431-2438. doi: 10.1002/j.1460-2075.1990.tb07419.x

 

  1. Avila J, Wandosell F, Hernández F. Role of glycogen synthase kinase-3 in Alzheimer’s disease pathogenesis and glycogen synthase kinase-3 inhibitors. Expert Rev Neurother. 2010;10(5):703-710. doi: 10.1586/ern.10.40

 

  1. Zhou Q, Li S, Li M, et al. Human tau accumulation promotes glycogen synthase kinase-3β acetylation and thus upregulates the kinase: A vicious cycle in Alzheimer neurodegeneration. eBioMedicine. 2022;78:103970. doi: 10.1016/j.ebiom.2022.103970

 

  1. Hooper C, Markevich V, Plattner F, et al. Glycogen synthase kinase-3 inhibition is integral to long-term potentiation. Eur J Neurosci. 2007;25(1):81-86. doi: 10.1111/j.1460-9568.2006.05245.x

 

  1. Pei JJ, Braak E, Braak H, et al. Distribution of active glycogen synthase kinase 3beta (GSK-3beta) in brains staged for Alzheimer disease neurofibrillary changes. J Neuropathol Exp Neurol. 1999;58(9):1010-1019. doi: 10.1097/00005072-199909000-00011

 

  1. Mukai F, Ishiguro K, Sano Y, et al. Alternative splicing isoform of tau protein kinase I/glycogen synthase kinase 3beta. J Neurochem. 2002;81(5):1073-1083. doi: 10.1046/j.1471-4159.2002.00918.x

 

  1. Zhou J, Freeman TA, Ahmad F, et al. GSK-3α is a central regulator of age-related pathologies in mice. J Clin Invest. 2013;123(4):1821-1832. doi: 10.1172/JCI64398

 

  1. Cheng Z, Han T, Yao J, et al. Targeting glycogen synthase kinase-3β for Alzheimer’s disease: Recent advances and future Prospects. Eur J Med Chem. 2024;265:116065. doi: 10.1016/j.ejmech.2023.116065

 

  1. Soutar MP, Kim WY, Williamson R, et al. Evidence that glycogen synthase kinase-3 isoforms have distinct substrate preference in the brain. J Neurochem. 2010;115(4):974-983. doi: 10.1111/j.1471-4159.2010.06988.x

 

  1. Chauhan N, Paliwal S, Jain S, et al. GSK-3β and its Inhibitors in Alzheimer’s Disease: A Recent Update. Mini Rev Med Chem. 2022;22(22):2881-2895. doi: 10.2174/1389557522666220420094317

 

  1. Maurin H, Lechat B, Dewachter I, et al. Neurological characterization of mice deficient in GSK3α highlight pleiotropic physiological functions in cognition and pathological activity as Tau kinase. Mol Brain. 2013;6(1):27. doi: 10.1186/1756-6606-6-27

 

  1. Hurtado DE, Molina-Porcel L, Carroll JC, et al. Selectively silencing GSK-3 isoforms reduces plaques and tangles in mouse models of Alzheimer’s disease. J Neurosci. 2012;32(21):7392-7402. doi: 10.1523/JNEUROSCI.0889-12.2012

 

  1. Latapy C, Rioux V, Guitton MJ, et al. Selective deletion of forebrain glycogen synthase kinase 3β reveals a central role in serotonin-sensitive anxiety and social behaviour. Philos Trans R Soc Lond B Biol Sci. 2012;367(1601):2460-2474. doi: 10.1098/rstb.2012.0094

 

  1. Nishizaki T. DCP-LA, a New Strategy for Alzheimer’s Disease Therapy. J Neurol Neuromedicine. 2017;2(9):1-8. doi: 10.29245/2572.942X/2017/9.1159

 

  1. Zhao J, Wei M, Guo M, et al. GSK3: A potential target and pending issues for treatment of Alzheimer’s disease. CNS Neurosci Ther. 2024;30(7):e14818. doi: 10.1111/cns.14818

 

  1. Kobayashi S, Ishiguro K, Omori A, et al. A cdc2-related kinase PSSALRE/cdk5 is homologous with the 30 kDa subunit of tau protein kinase II, a proline-directed protein kinase associated with microtubule. FEBS Lett. 1993;335(2):171- 175. doi: 10.1016/0014-5793(93)80723-8

 

  1. Smith DS, Tsai LH. Cdk5 behind the wheel: a role in trafficking and transport? Trends Cell Biol. 2002;12(1):28-36. doi: 10.1016/s0962-8924(01)02181-x

 

  1. Boutajangout A, Sigurdsson EM, Krishnamurthy PK. Tau as a therapeutic target for Alzheimer’s disease. Curr Alzheimer Res. 2011;8(6):666-677. doi: 10.2174/156720511796717195

 

  1. Ahlijanian MK, Barrezueta NX, Williams RD, et al. Hyperphosphorylated tau and neurofilament and cytoskeletal disruptions in mice overexpressing human p25, an activator of cdk5. Proc Natl Acad Sci USA. 2000;97(6):2910-2915. doi: 10.1073/pnas.040577797

 

  1. Cruz JC, Tseng HC, Goldman JA, et al. Aberrant Cdk5 activation by p25 triggers pathological events leading to neurodegeneration and neurofibrillary tangles. Neuron. 2003;40(3):471-483. doi: 10.1016/s0896-6273(03)00627-5

 

  1. Piedrahita D, Hernández I, López-Tobón A, et al. Silencing of CDK5 reduces neurofibrillary tangles in transgenic Alzheimer’s mice. J Neurosci. 2010;30(42):13966-13976. doi: 10.1523/JNEUROSCI.3637-10.2010

 

  1. López-Tobón A, Castro-Álvarez JF, Piedrahita D, et al. Silencing of CDK5 as potential therapy for Alzheimer’s disease. Rev Neurosci. 2011;22(2):143-152. doi: 10.1515/RNS.2011.015

 

  1. Venerando A, Ruzzene M, Pinna LA. Casein kinase: the triple meaning of a misnomer. Biochem J. 2014;460(2):141- 156. doi: 10.1042/BJ20140178

 

  1. Hathaway GM, Tuazon PT, Traugh JA. Casein kinase I. Methods in Enzymol. 1983;99:308-317. doi: 10.1016/0076-6879(83)99066-3

 

  1. Hathaway GM, Traugh JA. Casein kinase II. Methods in Enzymol. 1983;99:317-331. doi: 10.1016/0076-6879(83)99067-5

 

  1. Chauhan A, Chauhan VP, Murakami N, et al. Amyloid beta-protein stimulates casein kinase I and casein kinase II activities. Brain Res. 1993;629(1):47-52. doi: 10.1016/0006-8993(93)90479-7

 

  1. Díaz-Nido J, Serrano L, Méndez E, et al. A casein kinase II-related activity is involved in phosphorylation of microtubule-associated protein MAP-1B during neuroblastoma cell differentiation. J Cell Biol. 1988;106(6):2057-2065. doi: 10.1083/jcb.106.6.2057

 

  1. Walter J, Schindzielorz A, Hartung B, et al. Phosphorylation of the beta-amyloid precursor protein at the cell surface by ectocasein kinases 1 and 2. J Biol Chem. 2000;275(31):23523- 23529. doi: 10.1074/jbc.M002850200

 

  1. Perez DI, Gil C, Martinez A. Protein kinases CK1 and CK2 as new targets for neurodegenerative diseases. Med Res Rev. 2011;31(6):924-954. doi: 10.1002/med.20207

 

  1. Li G, Yin H, Kuret J. Casein kinase 1 delta phosphorylates tau and disrupts its binding to microtubules. J Biol Chem. 2004;279(16):15938-15945. doi: 10.1074/jbc.M314116200

 

  1. Hanger DP, Byers HL, Wray S, et al. Novel phosphorylation sites in tau from Alzheimer brain support a role for casein kinase 1 in disease pathogenesis. J Biol Chem. 2007;282(32):23645-23654. doi: 10.1074/jbc.M703269200

 

  1. Oumata N, Bettayeb K, Ferandin Y, et al. Roscovitine-derived, dual-specificity inhibitors of cyclin-dependent kinases and casein kinases 1. J Med Chem. 2008;51(17):5229- 5242. doi: 10.1021/jm800109e

 

  1. Serrano L, Hernández MA, Díaz-Nido J, et al. Association of casein kinase II with microtubules. Exp Cell Res. 1989;181(1):263-272. doi: 10.1016/0014-4827(89)90200-0

 

  1. Iimoto DS, Masliah E, DeTeresa R, et al. Aberrant casein kinase II in Alzheimer’s disease. Brain Res. 1990;507(2):273- 280. doi: 10.1016/0006-8993(90)90282-g

 

  1. Litchfield DW. Protein kinase CK2: structure, regulation and role in cellular decisions of life and death. Biochem. J. 2003;369(1):1-15. doi: 10.1042/BJ20021469

 

  1. Singh NN, Ramji DP. Transforming growth factor-beta-induced expression of the apolipoprotein E gene requires c-Jun N-terminal kinase, p38 kinase, and casein kinase 2. Arter Thromb Vasc Biol. 2006;26(6):1323-1329. doi: 10.1161/01.ATV.0000220383.19192.55

 

  1. Kramerov AA, Saghizadeh M, Pan H, et al. Expression of protein kinase CK2 in astroglial cells of normal and neovascularized retina. Am J Pathol. 2006;168(5):1722-1736. doi: 10.2353/ajpath.2006.050533

 

  1. Rosenberger AF, Morrema TH, Gerritsen WH, et al. Increased occurrence of protein kinase CK2 in astrocytes in Alzheimer’s disease pathology. J Neuroinflammation. 2016;13(1):4. doi: 10.1186/s12974-015-0470-x

 

  1. Tassan JP, Le Goff X. An overview of the KIN1/PAR-1/ MARK kinase family. Biol Cell. 2004;96(3):193-199. doi: 10.1016/j.biolcel.2003.10.009

 

  1. Matenia D, Mandelkow EM. The tau of MARK: a polarized view of the cytoskeleton. Trends Biochem. Sci. 2009;34(7):332-342. doi: 10.1016/j.tibs.2009.03.008

 

  1. Wu Q, DiBona VL, Bernard LP, et al. The polarity protein partitioning-defective 1 (PAR-1) regulates dendritic spine morphogenesis through phosphorylating postsynaptic density protein 95 (PSD-95). J Biol Chem. 2012;287(36):30781-30788. doi: 10.1074/jbc.M112.351452

 

  1. Biernat J, Wu YZ, Timm T, et al. Protein kinase MARK/ PAR-1 is required for neurite outgrowth and establishment of neuronal polarity. Mol Biol Cell. 2002;13(11):4013-4028. doi: 10.1091/mbc.02-03-0046

 

  1. Meijer L, Thunnissen AM, White AW, et al. Inhibition of cyclin-dependent kinases, GSK-3beta and CK1 by hymenialdisine, a marine sponge constituent. Chem Biol. 2000;7(1):51-63. doi: 10.1016/s1074-5521(00)00063-6

 

  1. Timm T, Balusamy K, Li X, et al. Glycogen synthase kinase (GSK) 3beta directly phosphorylates Serine 212 in the regulatory loop and inhibits microtubule affinity-regulating kinase (MARK) 2. J Biol Chem. 2008;283(27):18873-18882. doi: 10.1074/jbc.M706596200

 

  1. Song J, Park KA, Lee WT, et al. Apoptosis signal regulating kinase 1 (ASK1): potential as a therapeutic target for Alzheimer’s disease. Int J Mol Sci. 2014;15(2):2119-2129. doi: 10.3390/ijms15022119

 

  1. Hueber AO, Zörnig M, Lyon D, et al. Requirement for the CD95 receptor-ligand pathway in c-Myc-induced apoptosis. Science. 1997;278(5341):1305-1309. doi: 10.1126/science.278.5341.1305

 

  1. Peel AL, Sorscher N, Kim JY, et al. Tau phosphorylation in Alzheimer’s disease: potential involvement of an APP-MAP kinase complex. Neuromolecular Med. 2004;5(3):205-218. doi: 10.1385/NMM:5:3:205

 

  1. Cholerton B, Baker LD, Craft S. Insulin, cognition, and dementia. Eur J Pharm. 2013;719(1-3):170-179. doi: 10.1016/j.ejphar.2013.08.008

 

  1. Nishikawa T, Kukidome D, Sonoda K, et al. Impact of mitochondrial ROS production in the pathogenesis of insulin resistance. Diabetes Res Clin Pract. 2007;77(3):S161-S164. doi: 10.1016/j.diabres.2007.01.071

 

  1. Cheon SY, Cho KJ, Song J, et al. Knockdown of apoptosis signal-regulating kinase 1 affects ischaemia-induced astrocyte activation and glial scar formation. Eur J Neurosci. 2016;43(7):912-922. doi: 10.1111/ejn.13175

 

  1. Dhillon AS, Hagan S, Rath O, et al. MAP kinase signalling pathways in cancer. Oncogene. 2007;26(22):3279-3290. doi: 10.1038/sj.onc.1210421

 

  1. Koul HK, Pal M, Koul S. Role of p38 MAP Kinase Signal Transduction in Solid Tumors. Genes Cancer. 2013;4(9- 10):342-359. doi: 10.1177/1947601913507951

 

  1. Yang Y, Kim SC, Yu T, et al. Functional roles of p38 mitogen-activated protein kinase in macrophage-mediated inflammatory responses. Mediat Inflamm. 2014;2014:1-13. doi: 10.1155/2014/352371

 

  1. Kim EK, Choi EJ. Compromised MAPK signalling in human diseases: an update. Arch Toxicol. 2015;89(6):867-882. doi: 10.1007/s00204-015-1472-2

 

  1. Roy S, Roy S, Rana A, et al. The role of p38 MAPK pathway in p53 compromised state and telomere mediated DNA damage response. Mutat Res Genet Toxicol Env Mutagen. 2018;836:89-97. doi: 10.1016/j.mrgentox.2018.05.018

 

  1. New L, Han J. The p38 MAP kinase pathway and its biological function. Trends Cardiovasc Med. 1998;8(5):220- 228. doi: 10.1016/s1050-1738(98)00012-7

 

  1. Whitmarsh AJ, Davis RJ. Role of mitogen-activated protein kinase kinase 4 in cancer. Oncogene. 2007;26(22):3172-3184. doi: 10.1038/sj.onc.1210410

 

  1. Cuadrado A, Nebreda AR. Mechanisms and functions of p38 MAPK signalling. Biochem J. 2010;429(3):403-417. doi: 10.1042/BJ20100323

 

  1. Lee JK, Kim NJ. Recent Advances in the Inhibition of p38 MAPK as a Potential Strategy for the Treatment of Alzheimer’s Disease. Molecules. 2017;22(8):1287. doi: 10.3390/molecules22081287

 

  1. Qin P, Ran Y, Liu Y, et al. Recent advances of small molecule JNK3 inhibitors for Alzheimer’s disease. Bioorg Chem. 2022;128:106090. doi: 10.1016/j.bioorg.2022.106090

 

  1. Swahn BM, Xue Y, Arzel E, et al. Design and synthesis of 2’-anilino-4,4’-bipyridines as selective inhibitors of c-Jun N-terminal kinase-3. Bioorg Med Chem Lett. 2006;16(5):1397-1401. doi: 10.1016/j.bmcl.2005.11.039

 

  1. Yoon SO, Park DJ, Ryu JC, et al. JNK3 perpetuates metabolic stress induced by Aβ peptides. Neuron. 2012;75(5):824-837. doi: 10.1016/j.neuron.2012.06.024

 

  1. Mensch J, Melis A, Mackie C, et al. Evaluation of various PAMPA models to identify the most discriminating method for the prediction of BBB permeability. Eur J Pharm Biopharm. 2010;74(3):495-502. doi: 10.1016/j.ejpb.2010.01.003

 

  1. Li C, Liu T, Cui X, et al. Development of in vitro pharmacokinetic screens using Caco-2, human hepatocyte, and Caco-2/human hepatocyte hybrid systems for the prediction of oral bioavailability in humans. J Biomol Screen. 2007;12(8):1084-1091. doi: 10.1177/1087057107308892

 

  1. Garcia-Alloza M, Robbins EM, Zhang-Nunes SX, et al. Characterization of amyloid deposition in the APPswe/ PS1dE9 mouse model of Alzheimer disease. Neurobiol Dis. 2006;24(3):516-524. doi: 10.1016/j.nbd.2006.08.017

 

  1. Duyckaerts C, Delatour B, Potier MC. Classification and basic pathology of Alzheimer disease. Acta Neuropathol. 2009;118(1):5-36. doi: 10.1007/s00401-009-0532-1

 

  1. Hardy JA, Higgins GA. Alzheimer’s disease: the amyloid cascade hypothesis. Science. 1992;256:184-185. doi: 10.1126/science.1566067

 

  1. Crews L, Masliah E. Molecular mechanisms of neurodegeneration in Alzheimer’s disease. Hum Mol Genet. 2010;19(R1):R12-R20. doi: 10.1093/hmg/ddq160

 

  1. Tuffaha GO, Hatmal MM, Taha MO. Discovery of new JNK3 inhibitory chemotypes via QSAR-Guided selection of docking-based pharmacophores and comparison with other structure-based pharmacophore modeling methods. J Mol Graph Model. 2019;91:30-51. doi: 10.1016/j.jmgm.2019.05.015

 

  1. Zhou Q, Wang M, Du Y, et al. Inhibition of c-Jun N-terminal kinase activation reverses Alzheimer disease phenotypes in APPswe/PS1dE9 mice. Ann Neurol. 2015;77(4):637-654. doi: 10.1002/ana.24361

 

  1. Zheng K, Iqbal S, Hernandez P, et al. Correction to Design and Synthesis of Highly Potent and Isoform Selective JNK3 Inhibitors: SAR Studies on Aminopyrazole Derivatives. J Med Chem. 2016;59(19):9276. doi: 10.1021/acs.jmedchem.6b01369

 

  1. Jun J, Baek J, Yang S, et al. Discovery of a Potent and Selective JNK3 Inhibitor with Neuroprotective Effect Against Amyloid β-Induced Neurotoxicity in Primary Rat Neurons. Int J Mol Sci. 2021;22(20):11084. doi: 10.3390/ijms222011084

 

  1. Bennett BL, Sasaki DT, Murray BW, et al. SP600125, an anthrapyrazolone inhibitor of Jun N-terminal kinase. Proc Natl Acad Sci USA. 2001;98(24):13681-13686. doi: 10.1073/pnas.251194298

 

  1. Geng J, Ito Y, Shi L, et al. Regulation of RIPK1 activation by TAK1-mediated phosphorylation dictates apoptosis and necroptosis. Nat Commun. 2017;8(1):359. doi: 10.1038/s41467-017-00406-w

 

  1. Thapa RJ, Nogusa S, Chen P, et al. Interferon-induced RIP1/RIP3-mediated necrosis requires PKR and is licensed by FADD and caspases. Proc Natl Acad Sci USA. 2013;110(33):E3109-E3118. doi: 10.1073/pnas.1301218110

 

  1. Dondelinger Y, Delanghe T, Rojas-Rivera D, et al. MK2 phosphorylation of RIPK1 regulates TNF-mediated cell death. Nat Cell Biol. 2017;19(10):1237-1247. doi: 10.1038/ncb3608

 

  1. Dondelinger Y, Delanghe T, Priem D, et al. Serine 25 phosphorylation inhibits RIPK1 kinase-dependent cell death in models of infection and inflammation. Nat Commun. 2019;10(1):1729. doi: 10.1038/s41467-019-09690-0.

 

  1. Jaco I, Annibaldi A, Lalaoui N, et al. MK2 Phosphorylates RIPK1 to Prevent TNF-Induced Cell Death. Mol Cell. 2017;66(5):698-710.e5. doi: 10.1016/j.molcel.2017.05.003

 

  1. Caccamo A, Branca C, Piras IS, et al. Necroptosis activation in Alzheimer’s disease. Nat Neurosci. 2017;20(9):1236-1246. doi: 10.1038/nn.4608

 

  1. Koper MJ, Van Schoor E, Ospitalieri S, et al. Necrosome complex detected in granulovacuolar degeneration is associated with neuronal loss in Alzheimer’s disease. Acta Neuropathol. 2020;139(3):463-484. doi: 10.1007/s00401-019-02103-y

 

  1. Najjar M, Saleh D, Zelic M, et al. RIPK1 and RIPK3 Kinases Promote Cell-Death-Independent Inflammation by Toll-like Receptor 4. Immunity. 2016;45(1):46-59. doi: 10.1016/j.immuni.2016.06.007

 

  1. Ofengeim D, Mazzitelli S, Ito Y, et al. RIPK1 mediates a disease-associated microglial response in Alzheimer’s disease. Proc Natl Acad Sci USA. 2017;114(41). doi: 10.1073/pnas.1714175114

 

  1. Grievink HW, Heuberger JAAC, Huang F, et al. DNL104, a Centrally Penetrant RIPK1 Inhibitor, Inhibits RIP1 Kinase Phosphorylation in a Randomized Phase I Ascending Dose Study in Healthy Volunteers. Clin Pharmacol Ther. 2020;107(2):406-414. doi: 10.1002/cpt.1615

 

  1. Newton K. RIPK1 and RIPK3: critical regulators of inflammation and cell death. Trends Cell Biol. 2015;25(6):347- 353. doi: 10.1016/j.tcb.2015.01.001

 

  1. Shearman MS, Shinomura T, Oda T, et al. Synaptosomal protein kinase C subspecies: A. Dynamic changes in the hippocampus and cerebellar cortex concomitant with synaptogenesis. J Neurochem. 1991;56(4):1255-1262. doi: 10.1111/j.1471-4159.1991.tb11419.x

 

  1. Nelson TJ, Collin C, Alkon DL. Isolation of a G protein that is modified by learning and reduces potassium currents in Hermissenda. Science. 1990;247(4949):1479-1483. doi: 10.1126/science.247.4949.1479

 

  1. Hongpaisan J, Alkon DL. A structural basis for enhancement of long-term associative memory in single dendritic spines regulated by PKC. Proc Natl Acad Sci USA. 2007;104(49):19571-19576. doi: 10.1073/pnas.0709311104

 

  1. Khan TK, Sen A, Hongpaisan J, et al. PKCε deficits in Alzheimer’s disease brains and skin fibroblasts. J Alzheimers Dis. 2014;43(2):491-509. doi: 10.3233/JAD-141221

 

  1. Hongpaisan J, Sun MK, Alkon DL. PKC ε activation prevents synaptic loss, Aβ elevation, and cognitive deficits in Alzheimer’s disease transgenic mice. J Neurosci. 2011;31(2):630-643. doi: 10.1523/JNEUROSCI.5209-10.2011

 

  1. Basheer N, Smolek T, Hassan I, et al. Does modulation of tau hyperphosphorylation represent a reasonable therapeutic strategy for Alzheimer’s disease? From preclinical studies to the clinical trials. Mol Psychiatry. 2023;28(6):2197-214. doi: 10.1038/s41380-023-02113-z

 

  1. Tan Z, Turner RC, Leon RL, et al. Bryostatin improves survival and reduces ischemic brain injury in aged rats after acute ischemic stroke. Stroke. 2013;44(10):3490-3497.

doi: 10.1161/STROKEAHA.113.002411

 

  1. Sun MK, Hongpaisan J, Lim CS, et al. Bryostatin-1 restores hippocampal synapses and spatial learning and memory in adult fragile X mice. J Pharmacol Exp Ther. 2014;349(3):393- 401. doi: 10.1124/jpet.114.214098

 

  1. Cai Z, Yan LJ, Li K, et al. Roles of AMP-activated protein kinase in Alzheimer’s disease. Neuromolecular Med. 2012;14(1):1-14. doi: 10.1007/s12017-012-8173-2

 

  1. Zhang BB, Zhou G, Li C. AMPK: an emerging drug target for diabetes and the metabolic syndrome. Cell Metab. 2009;9(5):407-416. doi: 10.1016/j.cmet.2009.03.012

 

  1. Seixas da Silva GS, Melo HM, Lourenco MV, et al. Amyloid-β oligomers transiently inhibit AMP-activated kinase and cause metabolic defects in hippocampal neurons. J Biol Chem. 2017;292(18):7395-7406. doi: 10.1074/jbc.M116.753525

 

  1. Domise M, Didier S, Marinangeli C, et al. AMP-activated protein kinase modulates tau phosphorylation and tau pathology in vivo. Sci Rep. 2016;6(1):26758. doi: 10.1038/srep26758

 

  1. Schrade K, Tröger J, Eldahshan A, et al. An AKAP-Lbc- RhoA interaction inhibitor promotes the translocation of aquaporin-2 to the plasma membrane of renal collecting duct principal cells. PLoS ONE. 2018;13(1):e0191423. doi: 10.1371/journal.pone.0191423

 

  1. Homma Y, Hiragi S, Fukuda M. Rab family of small GTPases: an updated view on their regulation and functions. FEBS J. 2021;288(1):36-55. doi: 10.1111/febs.15453.

 

  1. Cai R, Wang Y, Huang Z, et al. Role of RhoA/ROCK signalling in Alzheimer’s disease. Behav Brain Res. 2021;414:113481. doi: 10.1016/j.bbr.2021.113481

 

  1. Hamano T, Shirafuji N, Yen SH, et al. Rho-kinase ROCK inhibitors reduce oligomeric tau protein. Neurobiol Aging. 2020;89:41-54. doi: 10.1016/j.neurobiolaging.2019.12.009

 

  1. Giannakouros T, Nikolakaki E, Mylonis I, et al. Serine-arginine protein kinases: a small protein kinase family with a large cellular presence. FEBS J. 2011;278(4):570-586. doi: 10.1111/j.1742-4658.2010.07987.x

 

  1. Koizumi J, Okamoto Y, Onogi H, et al. The subcellular localization of SF2/ASF is regulated by direct interaction with SR protein kinases (SRPKs). J Biol Chem. 1999;274(16):11125-11131. doi: 10.1074/jbc.274.16.11125

 

  1. Jang SW, Liu X, Fu H, et al. Interaction of Akt-phosphorylated SRPK2 with 14-3-3 mediates cell cycle and cell death in neurons. J Biol Chem. 2009;284(36):24512-24525. doi: 10.1074/jbc.M109.026237

 

  1. Hong Y, Chan CB, Kwon IS, et al. SRPK2 phosphorylates tau and mediates the cognitive defects in Alzheimer’s disease. J Neurosci. 2012;32(48):17262-17272. doi: 10.1523/JNEUROSCI.3300-12.2012

 

  1. Du Z, Lovly CM. Mechanisms of receptor tyrosine kinase activation in cancer. Mol Cancer.2018;17(1):58. doi: 10.1186/s12943-018-0782-4

 

  1. Kim M, Baek M, Kim DJ. Protein Tyrosine Signalling and its Potential Therapeutic Implications in Carcinogenesis. Curr Pharm Des. 2017;23(29):4226-4246. doi: 10.2174/1381612823666170616082125

 

  1. Rosenberger AF, Hilhorst R, Coart E, et al. Protein Kinase Activity Decreases with Higher Braak Stages of Alzheimer’s Disease Pathology. J Alzheimers Dis. 2016;49(4):927-943. doi: 10.3233/JAD-150429

 

  1. Guan JL, Shalloway D. Regulation of focal adhesion-associated protein tyrosine kinase by both cellular adhesion and oncogenic transformation. Nature. 1992;358(6388):690- 692. doi: 10.1038/358690a0

 

  1. Luo YQ, Hirashima N, Li YH, et al. Physiological levels of beta-amyloid increase tyrosine phosphorylation and cytosolic calcium. Brain Res. 1995;681(1-2):65-74. doi: 10.1016/0006-8993(95)00282-u

 

  1. McDonald DR, Brunden KR, Landreth GE. Amyloid fibrils activate tyrosine kinase-dependent signalling and superoxide production in microglia. J Neurosci. 1997;17(7):2284-2294. doi: 10.1523/JNEUROSCI.17-07-02284.1997

 

  1. Leng F, Edison P. Neuroinflammation and microglial activation in Alzheimer disease: where do we go from here? Nat Rev Neurol. 2021;17(3):157-172. doi: 10.1038/s41582-020-00435-y

 

  1. Panjarian S, Iacob RE, Chen S, et al. Structure and dynamic regulation of Abl kinases. J Biol Chem. 2013;288(8):5443- 5450. doi: 10.1074/jbc.R112.438382

 

  1. Schlatterer SD, Acker CM, Davies P. c-Abl in neurodegenerative disease. J Mol Neurosci. 2011;45(3):445- 452. doi: 10.1007/s12031-011-9588-1

 

  1. Sciaccaluga M, Megaro A, Bellomo G, et al. An Unbalanced Synaptic Transmission: Cause or Consequence of the Amyloid Oligomers Neurotoxicity? Int J Mol Sci. 2021;22(11):5991. doi: 10.3390/ijms22115991

 

  1. Galanis C, Fellenz M, Becker D, et al. Amyloid-Beta Mediates Homeostatic Synaptic Plasticity. J Neurosci. 2021;41(24):5157-5172. doi: 10.1523/JNEUROSCI.1820-20.2021

 

  1. Ren Y, Chen J, Wu X, et al. Role of c-Abl-GSK3β Signalling in MPP+-Induced Autophagy-Lysosomal Dysfunction. Toxicol Sci. 2018;165(1):232-243. doi: 10.1093/toxsci/kfy155

 

  1. La Barbera L, Vedele F, Nobili A, et al. Nilotinib restores memory function by preventing dopaminergic neuron degeneration in a mouse model of Alzheimer’s Disease. Prog Neurobiol. 2021;202:102031. doi: 10.1016/j.pneurobio.2021.102031

 

  1. Turner RS, Hebron ML, Lawler A, et al. Nilotinib Effects on Safety, Tolerability, and Biomarkers in Alzheimer’s Disease. Ann Neurol. 2020;88(1):183-194. doi: 10.1002/ana.25775

 

  1. Hu B, Duan S, Wang Z, et al. Insights Into the Role of CSF1R in the Central Nervous System and Neurological Disorders. Front. Aging Neurosci. 2021;13:789834. doi: 10.3389/fnagi.2021.789834

 

  1. Greter M, Lelios I, Pelczar P, et al. Stroma-derived interleukin-34 controls the development and maintenance of Langerhans cells and the maintenance of microglia. Immunity. 2012;37(6):1050-1060. doi: 10.1016/j.immuni.2012.11.001

 

  1. Wang Y, Ulland TK, Ulrich JD, et al. TREM2-mediated early microglial response limits diffusion and toxicity of amyloid plaques. J Exp Med. 2016;213(5):667-675. doi: 10.1084/jem.20151948

 

  1. Chitu V, Gokhan Ş, Nandi S, et al. Emerging Roles for CSF-1 Receptor and its Ligands in the Nervous System. Trends Neurosci. 2016;39(6):378-393. doi: 10.1016/j.tins.2016.03.005

 

  1. Easley-Neal C, Foreman O, Sharma N, et al. CSF1R Ligands IL-34 and CSF1 Are Differentially Required for Microglia Development and Maintenance in White and Gray Matter Brain Regions. Front Immunol. 2019;10:2199. doi: 10.3389/fimmu.2019.02199

 

  1. Thion MS, Garel S. On place and time: microglia in embryonic and perinatal brain development. Curr Opin Neurobiol. 2017;47:121-130. doi: 10.1016/j.conb.2017.10.004

 

  1. Sirkis DW, Bonham LW, Yokoyama JS. The Role of Microglia in Inherited White-Matter Disorders and Connections to Frontotemporal Dementia. Appl Clin Genet. 2021;14:195- 207. doi: 10.2147/TACG.S245029

 

  1. Soto-Diaz K, Vailati-Riboni M, Louie AY, et al. Treatment With the CSF1R Antagonist GW2580, Sensitizes Microglia to Reactive Oxygen Species. Front Immunol. 2021;12:734349. doi: 10.3389/fimmu.2021.734349

 

  1. Gendron TF, Petrucelli L. The role of tau in neurodegeneration. Mol Neurodegener. 2009;4(1):13. doi: 10.1186/1750-1326-4-13.

 

  1. Kuret J, Johnson GS, Cha D, et al. Casein kinase 1 is tightly associated with paired-helical filaments isolated from Alzheimer’s disease brain. J Neurochem. 1997;69(6):2506- 2515. doi: 10.1046/j.1471-4159.1997.69062506.x

 

  1. Yamaguchi H, Ishiguro K, Uchida T, et al. Preferential labeling of Alzheimer neurofibrillary tangles with antisera for tau protein kinase (TPK) I/glycogen synthase kinase-3 beta and cyclin-dependent kinase 5, a component of TPK II. Acta Neuropathol. 1996;92(3):232-241. doi: 10.1007/s004010050

 

  1. Pei JJ, Braak H, An WL, et al. Up-regulation of mitogen-activated protein kinases ERK1/2 and MEK1/2 is associated with the progression of neurofibrillary degeneration in Alzheimer’s disease. Brain Res Mol Brain Res. 2002;109(1- 2):45-55. doi: 10.1016/s0169-328x(02)00488-6

 

  1. Schwab C, DeMaggio AJ, Ghoshal N, et al. Casein kinase 1 delta is associated with pathological accumulation of tau in several neurodegenerative diseases. Neurobiol Aging. 2000;21(4):503-510. doi: 10.1016/s0197-4580(00)00110-x

 

  1. Hondius DC, Koopmans F, Leistner C, et al. The proteome of granulovacuolar degeneration and neurofibrillary tangles in Alzheimer’s disease. Acta Neuropathol. 2021;141(3):341- 358. doi: 10.1007/s00401-020-02261-4

 

  1. Yasojima K, Kuret J, DeMaggio AJ, et al. Casein kinase 1 delta mRNA is upregulated in Alzheimer disease brain. Brain Res. 2000;865(1):116-120. doi: 10.1016/s0006-8993(00)02200-9

 

  1. Hoshi M, Takashima A, Noguchi K, et al. Regulation of mitochondrial pyruvate dehydrogenase activity by tau protein kinase I/glycogen synthase kinase 3beta in brain. Proc Natl Acad Sci USA. 1996;93(7):2719-2723. doi: 10.1073/pnas.93.7.2719

 

  1. Flajolet M, He G, Heiman M, et al. Regulation of Alzheimer’s disease amyloid-beta formation by casein kinase I. Proc Natl Acad Sci USA. 2007;104(10):4159-4164. doi: 10.1073/pnas.0611236104
Share
Back to top
Advanced Neurology, Electronic ISSN: 2810-9619 Print ISSN: 3060-8589, Published by AccScience Publishing
We use cookies on our website to ensure you get the best experience.
Read more about our cookies here
Accept